Video

Nadofaragene firadenovec and the future of NMIBC care

Dr. Vikram M. Narayan describes treatment advances and next steps in non-muscle invasive bladder cancer.

Vikram M. Narayan, MD, of Emory University, Winship Cancer Institute, Atlanta, GA, discusses next steps with the novel intravesical gene-mediated therapy nadofaragene firadenovec and the overall future of the treatment paradigm for patients with non-muscle invasive bladder cancer (NMIBC).

Narayan says there are promising options, such as nadofaragene firadenovec, emerging for patients with BCG-unresponsive NMIBC. Some of the next steps, according to Narayan, are exploring combination regimens, assessing sequencing strategies, and developing biomarkers to determine which patients might respond best to treatments.

Related Videos
2 experts in this video
2 experts in this video
2 experts in this video
2 experts in this video
2 experts in this video
2 experts in this video
Timothy Lyon, MD, answers a question during a video interview
Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
1 expert is featured in this series.
Related Content
© 2025 MJH Life Sciences

All rights reserved.